{"id":"https://genegraph.clinicalgenome.org/r/45ebe3ab-6192-4e9d-bff8-82c49171d7acv1.0","type":"EvidenceStrengthAssertion","dc:description":"","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/45ebe3ab-6192-4e9d-bff8-82c49171d7ac","GCISnapshot":"https://genegraph.clinicalgenome.org/r/1a57ea10-6ca0-4311-94f1-0ad036a38ca6","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/1a57ea10-6ca0-4311-94f1-0ad036a38ca6_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10010","date":"2018-03-27T16:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/1a57ea10-6ca0-4311-94f1-0ad036a38ca6_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10010","date":"2020-09-01T00:00:00Z","role":"Publisher"}],"curationReasonDescription":"","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1a57ea10-6ca0-4311-94f1-0ad036a38ca6_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1a57ea10-6ca0-4311-94f1-0ad036a38ca6_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6894f1a1-c0c6-4838-bffa-dc1cc4f4f374","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c088cbe1-fa72-430b-a9ce-943e8e6e864c","type":"Finding","dc:description":"Heart and muscle rely on fatty acids as substrates. In mitochondrial metabolism disorders, the heart undergoes hypertrophic remodeling.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28916721","rdfs:label":"Loss of CPT2 in heart and muscle","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/1a57ea10-6ca0-4311-94f1-0ad036a38ca6_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3f963dcc-7a3a-4ff1-9151-aca9a0ba0c7f","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/afe2f877-8114-488b-91da-bba70e5efd7a","type":"FunctionalAlteration","dc:description":"Fatty acid oxidation was measured in lymphocytes and/or fibroblasts as the production of 3H20 from both palmitic and myristic acids (Brivet et al, 1995).  Mean values of CPT2 activities and LCFA oxidation were most often lower in infantile-form than adult-form patients.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12673791","rdfs:label":"Correlation between genotype and biochemical activity"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/1a57ea10-6ca0-4311-94f1-0ad036a38ca6_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f7de815f-405b-45f2-b5de-7fd668c378e6","type":"EvidenceLine","dc:description":"Well-known disease mechanism.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/827352a3-d5b8-4143-8d47-8d9200dbef91","type":"Finding","dc:description":"CPT2 is required for mitochondrial long-chain fatty acid oxidation. Individuals with CPT2 deficiency have an elevation of these metabolites in the serum since they are unable to utilize them.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16704352","rdfs:label":"Function","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/1a57ea10-6ca0-4311-94f1-0ad036a38ca6_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cd61d6b0-6bd6-44c6-afed-e3fb9b321bd9_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cfc1460b-0045-4524-b7aa-6f695628e211","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12410208","rdfs:label":"Patient 2","ageType":"AgeAtDeath","ageUnit":"Days","ageValue":3,"detectionMethod":"Using allele-specific oligonucleotide technology, exons 1, 3, 4, and 5 were evaluated for 6 mutations in the CPT 2 gene (P50H, S113L, Q413fs, R503C, G549D, and R31C) and 2 common mutations in AMPD1 (Q12X, P48L).","ethnicity":{"id":"cg:NotHispanicOrLatino"},"phenotypeFreeText":"CPT II activity in fibroblasts was 6% of control. CPT activity in skeletal muscle was 18% of normal.","phenotypes":["obo:HP_0001612","obo:HP_0006559","obo:HP_0002910","obo:HP_0001290","obo:HP_0001943","obo:HP_0001662","obo:HP_0002153","obo:HP_0000113","obo:HP_0002789","obo:HP_0006677","obo:HP_0000083","obo:HP_0000126"],"previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/cd61d6b0-6bd6-44c6-afed-e3fb9b321bd9_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12410208","allele":[{"id":"https://genegraph.clinicalgenome.org/r/4e1eceef-586e-47db-9813-abe880849191","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000098.2(CPT2):c.1239_1240delGA (p.Lys414Thrfs)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/92430"}},{"id":"https://genegraph.clinicalgenome.org/r/08e241b5-0e6a-40f1-ab1b-d2fb01c76f2c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"CPT2, 3-BP DEL/5-BP INS, NT109","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/8965"}}]}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/5471597a-3bfe-4733-8020-140b002422c4_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/de28577f-3058-489c-bd76-b630a0edfca8","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18550408","rdfs:label":"Case 2","ageType":"AgeAtDeath","ageUnit":"Days","detectionMethod":"Entire gene sequenced","firstTestingMethod":"PCR","phenotypeFreeText":"Plasma acylcarnitine profile showed elevation of all long-chain species (C16 15.62, C18:2 22.25, C18:1 289.85, newborn screen positive. Urinary free carnitine 63.5 and esterified 36.8 mmol/mol creatine. Plasma free carnitine normal, but esterified fraction was elevated (85.3). CPTII activity was 0.02 nmol/min/mg (ref 0.07-0.21).","phenotypes":["obo:HP_0000113","obo:HP_0001643","obo:HP_0012622","obo:HP_0008947","obo:HP_0002126","obo:HP_0002789","obo:HP_0000105","obo:HP_0001640","obo:HP_0004719"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/5471597a-3bfe-4733-8020-140b002422c4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18550408","allele":{"id":"https://genegraph.clinicalgenome.org/r/1dc3bab6-cf8f-4f36-96a3-1be6ec53fe2b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000098.2(CPT2):c.1923_1935delGAAGGCCTTAGAA (p.Lys642Thrfs)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/130892"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/114b8824-1b39-4866-9983-800cec2b9e6a_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/761b24da-601b-476b-8347-677c5b8b8266","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12410208","rdfs:label":"Patient 1","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":11,"detectionMethod":"Using allele-specific oligonucleotide technology, exons 1, 3, 4, and 5 were evaluated for 6 mutations in the CPT 2 gene (P50H, S113L, Q413fs, R503C, G549D, and R31C) and 2 common mutations in AMPD1 (Q12X, P48L).","phenotypeFreeText":"Increased long-chain species, decreased carnitine,palmitate oxidation in fibroblasts showed increase in palmitoylcarnitine. CPT II activity in fibroblasts was 17% of normal control.","phenotypes":["obo:HP_0001254","obo:HP_0001943","obo:HP_0002013","obo:HP_0025212"],"previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/114b8824-1b39-4866-9983-800cec2b9e6a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12410208","allele":[{"id":"https://genegraph.clinicalgenome.org/r/6a19be43-a721-4c62-96bf-f01721a0d143","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000098.2(CPT2):c.149C>A (p.Pro50His)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/8954"}},{"id":"https://genegraph.clinicalgenome.org/r/4e1eceef-586e-47db-9813-abe880849191"}]}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/7db5ba7c-57a7-43d5-9de2-012e88d322c0_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/054aec31-9f02-4268-a91e-5579c6ead55d","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18550408","rdfs:label":"Case 4","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":15,"detectionMethod":"Entire gene sequenced","firstTestingMethod":"PCR","phenotypeFreeText":"Precipitating factors were at the beginning of infection diseases, fasting, and exercise. In labeled palmitate or linoleate uptake studies, long-chain acylcarnitines accumulated consistent with CPTII deficiency. CPTII activity in fibroblasts was 0.006 (ref 0.24).","phenotypes":["obo:HP_0001325","obo:HP_0025215","obo:HP_0200128","obo:HP_0002240","obo:HP_0006929","obo:HP_0004911"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/7db5ba7c-57a7-43d5-9de2-012e88d322c0_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18550408","allele":{"id":"https://genegraph.clinicalgenome.org/r/96db9c8c-24a0-4aa7-a137-1fc78f6c7c0f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000098.2(CPT2):c.359A>G (p.Tyr120Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/8968"}}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/b5bc4fad-bd55-4875-a8b7-1b94af62a5f8_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9a43edfd-39eb-4734-ab42-ffb8f72bc8ca","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8358442","rdfs:label":"Ser113Leu homozygote","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"PCR on genomic DNA, restriction enzyme digestion.","phenotypeFreeText":"Adult myopathic form of CPTII deficiency.","previousTesting":false,"previousTestingDescription":"","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/b5bc4fad-bd55-4875-a8b7-1b94af62a5f8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8358442","allele":{"id":"https://genegraph.clinicalgenome.org/r/df3eb195-4c3b-477c-a09e-8bf8969e2eb0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000098.2(CPT2):c.338C>T (p.Ser113Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/8953"}}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/8cf0ea84-65e6-43cc-8360-2d5a6ff5e8c6_proband_score_evidence_line","type":"EvidenceLine","dc:description":"No functional evidence","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bf711793-cc32-4a4f-a5a9-af86f5270386","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18550408","rdfs:label":"Case 5","ageType":"AgeAtDeath","ageUnit":"Months","ageValue":18,"detectionMethod":"Entire gene sequenced","firstTestingMethod":"PCR","phenotypeFreeText":"Elevation of octenedioic acid. Acylcarnitine profile showed extreme elevation of long-chain acylcarnitines: C16 12.35 nmol/mL, C18:1 8.4 nmol/mL, C18:2 4.38 nmol/mL. CPTII activity was 11% of normal in fibroblasts. Developed secondary carnitine deficiency requiring supplementation. Died of severe, acute cardiomyopathy in metabolic crisis following RSV infection.","phenotypes":["obo:HP_0001987","obo:HP_0001695"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/8cf0ea84-65e6-43cc-8360-2d5a6ff5e8c6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18550408","allele":{"id":"https://genegraph.clinicalgenome.org/r/58f3888c-efb0-4949-ac22-67fd1bf85936","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000001.11:g.53211185C>T","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA312430"}}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/497043f6-91b7-4a46-a128-96ce98e443be_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/164649b3-3190-4c69-af10-6f68c2bb2c48","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1528846","rdfs:label":"DM","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":23,"detectionMethod":"PCR amplification and sequencing of CPTase II cDNA. Confirmed by PCR of genomic DNA and restriction enzyme digest.","phenotypeFreeText":"Coma, brain damage, 17 hour fast revealed mild hypoglycemia without ketone body production. Oxidation of palmitate was <25% of normal. Long, medium and short chain acyl-CoA dehydrogenases were normal, CPTase I activity was normal. CPTase II activity was reduced to 16.45, 8.8%, and 6.6% of normal fibroblasts, lymphoblasts, and skeletal muscle.","phenotypes":["obo:HP_0001250","obo:HP_0002098","obo:HP_0002240","obo:HP_0001644"],"previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/497043f6-91b7-4a46-a128-96ce98e443be_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1528846","allele":{"id":"https://genegraph.clinicalgenome.org/r/bca79c7f-d701-45c0-b5fb-a46e20f66c00","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000098.2(CPT2):c.1891C>T (p.Arg631Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/8952"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/e274dcef-7616-442d-8a7f-48643d5c6db7_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f0b696aa-9246-4239-8beb-8f35281d2376","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18550408","rdfs:label":"Case 3","ageType":"AgeAtDeath","ageUnit":"Days","ageValue":3,"detectionMethod":"Entire gene sequenced","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","phenotypeFreeText":"Elevated long-chain acylcarnitines: C14:1 482 nM, C14 779 nM, C16:1 1232 nM, C16 5507 nM, C18:1 4057 nM, C18 2190 nM. CPTII activity in skeletal muscle was 29.8 umol/min/g tissue (ref 51.2-104.4).","phenotypes":["obo:HP_0012110","obo:HP_0000803","obo:HP_0000105","obo:HP_0012759","obo:HP_0001712","obo:HP_0002119","obo:HP_0002518","obo:HP_0002539","obo:HP_0001640","obo:HP_0000800","obo:HP_0002126","obo:HP_0002281","obo:HP_0000107","obo:HP_0012703","obo:HP_0007109","obo:HP_0007229"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/e274dcef-7616-442d-8a7f-48643d5c6db7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18550408","allele":[{"id":"https://genegraph.clinicalgenome.org/r/b3c55a6a-d9b6-4615-9058-8dd6dcc5326a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000001.11:g.53200730C>G","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA340389039"}},{"id":"https://genegraph.clinicalgenome.org/r/e440f941-b642-465d-a9ef-da8e6b3efea3","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000001.11:g.53213402del","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA859280"}}]}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/b3ef9fa0-78bb-4305-94ca-94827e18d2c6_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0425e74c-5f1f-4255-a55b-17421e33dd84","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16996287","rdfs:label":"21-30","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"Entire gene sequenced.","firstTestingMethod":"PCR","phenotypeFreeText":"Muscle enzyme activity (from 6 individuals): CPT=11.7 +/- 4.0, CS=17.4 +/- 6.4, CPT/CS = 0.68 +/- 0.18","previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/b3ef9fa0-78bb-4305-94ca-94827e18d2c6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16996287","allele":[{"id":"https://genegraph.clinicalgenome.org/r/df3eb195-4c3b-477c-a09e-8bf8969e2eb0"},{"id":"https://genegraph.clinicalgenome.org/r/4e1eceef-586e-47db-9813-abe880849191"}]}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/1a57ea10-6ca0-4311-94f1-0ad036a38ca6_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/dd3949e4-aab0-4e9a-8105-3e54b1602f0f_proband_segregation","type":"FamilyCosegregation","dc:description":"Not enough segregations.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1528846","rdfs:label":"M","estimatedLodScore":0.12,"family":{"id":"https://genegraph.clinicalgenome.org/r/dd3949e4-aab0-4e9a-8105-3e54b1602f0f","type":"Family","rdfs:label":"M","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/164649b3-3190-4c69-af10-6f68c2bb2c48"}},"meetsInclusionCriteria":false,"phenotypeFreeText":"Only 1 affected individual in the family.","phenotypeNegativeAlleleNegative":1,"phenotypePositiveAllelePositive":1,"proband":{"id":"https://genegraph.clinicalgenome.org/r/164649b3-3190-4c69-af10-6f68c2bb2c48"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/835adcb8-f821-46d5-ac7e-259fbd2465f3_proband_score_evidence_line","type":"EvidenceLine","dc:description":"No functional evidence","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b2906b8a-6b41-4d23-86c3-670ad8598ee6","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18550408","rdfs:label":"Case 1","ageType":"AgeAtDeath","ageUnit":"Days","ageValue":14,"detectionMethod":"Entire gene sequenced.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","phenotypeFreeText":"Blood sugar: 15 mg/dL; plasma CK: 1769 U/L; plasma carnitine profile: elevated C16 (39.68 nmol/mL), C18:2 (2.11), C18:1 (19.02) and C18 (6.80). CPTII activity in cultured fibroblasts was 0.02 nmol/min/mg protein (ref 0.07-0.21). Newborn screen positive.","phenotypes":["obo:HP_0001987","obo:HP_0001250","obo:HP_0003215","obo:HP_0001943","obo:HP_0001643","obo:HP_0000113"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/835adcb8-f821-46d5-ac7e-259fbd2465f3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18550408","allele":{"id":"https://genegraph.clinicalgenome.org/r/9e3bdf62-ad0f-410d-a004-958a6375f076","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000098.2(CPT2):c.680C>T (p.Pro227Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/8964"}}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.25}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":370,"specifiedBy":"GeneValidityCriteria6","strengthScore":16,"subject":{"id":"https://genegraph.clinicalgenome.org/r/20OogC4hoUE","type":"GeneValidityProposition","disease":"obo:MONDO_0015515","gene":"hgnc:2330","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_1a57ea10-6ca0-4311-94f1-0ad036a38ca6-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}